Entities / Company
Ginkgo Bioworks.
American biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 65
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
TD Cowen downgraded Ginkgo Bioworks shares on August 8, 2026.Some support2 reports
-
Ginkgo Bioworks delivered an automated phenotyping platform to support a research mission at Pacific Northwest National Laboratory.Some support2 reports
-
Evotec and Ginkgo Bioworks are both small-cap healthcare companies.Some support1 report
Gone quiet
No new reports in 90+ days-
Palantir Technologies and Ginkgo Bioworks are defining opposing models for biosecurity infrastructure.Some support1 report
-
Ginkgo Bioworks was part of the medical sector, and its stock outperformed the S&P 500 gain on June 26, 2025.Speculative1 report
-
Foundry, Ginkgo Bioworks, and CodeBase are proprietary cell programming platforms.Some support2 reports
-
Ginkgo Bioworks' stock performance on July 11, 2025, lagged the S&P 500 gain but led the Medical sector's gain.Some support1 report
-
Ginkgo Bioworks stock outperformed the S&P 500 gain on July 17, 2025, contrasting with a sector loss.Some support1 report
-
RAC provides modular hardware and Catalyst scheduling software to clients in the biopharma sector, including Ginkgo Bioworks.Some support1 report1 development inside
-
RAC automation enables high-throughput ADME profiling for Ginkgo Bioworks, which performs all work within the United States.Some support1 report
-
Ginkgo Bioworks stock trailed the S&P 500 on July 26, 2025, despite a market uptick, while operating within the broader medical and biomedical industries.Some support1 report
-
Ginkgo Bioworks began using Instagram and LinkedIn for its social media and professional networking presence.Some support1 report
-
Jason Kelly is co-founder and CEO of Ginkgo Bioworks.Some support2 reports
-
Ginkgo Bioworks reported operational challenges, including decreased R&D and G&A expenses and difficulties securing international contracts.Some support1 report
-
Illumina, Twist Bioscience, Ginkgo Bioworks, Amyris, Cargill, Moderna, and Vertex Pharmaceuticals are all key players in the AI in Synthetic Biology Market.Some support2 reports
-
Zacks provided stock analysis reports on Ginkgo Bioworks on August 13, 2025.Some support1 report
-
Ginkgo Bioworks announced the settlement of shareholder derivative actions on August 30, 2025.Some support1 report
-
Ginkgo Bioworks and Apheris formed a strategic partnership to launch the Antibody Developability Consortium.Some support1 report
-
Ginkgo Bioworks, Tangible Scientific, and Inductive Bio co-developed the ADME-One platform.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Ginkgo Bioworks this week
News at the entities that move Ginkgo Bioworks most-
TD Cowen OperationalAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves Ginkgo Bioworks
-
RAC TransactionalVoltas is focusing on the RAC business for near-term earnings, utilizing its Chennai plant for cost reduction through in-house manufacturing, while the Pantnagar plant contributes to overall production capacity.Moves Ginkgo Bioworks
-
Palantir Technologies OperationalMarket principle applied to company growth strategy involving Palantir Technologies and Jeff Bezos.Moves Ginkgo Bioworks
-
MIT OperationalGary Solomon sponsors ICM, and MIT utilized Ampex ARM10 memory in a recent development.Moves Ginkgo Bioworks
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Ginkgo Bioworks
-
University of Maryland OperationalShared origin of quantum computing pioneers involving Nvidia, the University of Maryland, and Duke University.Moves Ginkgo Bioworks
Connections
The 13 strongest of 65, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jason Kelly Structural
Jason Kelly is the co-founder, CEO, and minority owner of Ginkgo Bioworks.
-
TD Cowen Operational
TD Cowen issued a downgrade recommendation and lowered the price target for Ginkgo Bioworks shares.
-
Pacific Northwest National Laboratory Operational
The two entities are currently engaged in active discussions and projects focused on collaborative research and development.
-
RAC Transactional
RAC provides modular hardware and automation services that enable high-throughput ADME profiling for clients.
-
Northwestern University Operational
Ginkgo Bioworks is actively pursuing collaborative projects with Northwestern University.
-
Palantir Technologies Operational
Palantir and Ginkgo Bioworks compete by defining opposing models for biosecurity infrastructure.
-
MIT Operational
Ginkgo Bioworks is actively pursuing collaborative research projects with MIT.
-
Evotec Operational
Both companies are small-cap peers actively competing within the healthcare market.
Show all 13 connections
-
Nebula Shared context
The two companies operate within the same specialized biotech industry context, characterized by laboratory expansion.
-
Eric Nguyen Operational
Eric Nguyen and Ginkgo Bioworks are actively competing in the AI drug discovery market.
-
MarketBeat Mentioned together
MarketBeat reports consensus ratings and price targets regarding Ginkgo Bioworks.
-
University of Maryland Operational
Ginkgo Bioworks is actively pursuing collaborative projects with the University of Maryland.
-
Boston Shared context
Ginkgo Bioworks operates from its headquarters in the greater Boston area.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJune 2026
17 events- Ginkgo Bioworks delivered an automated phenotyping platform to support a research mission at Pacific Northwest National Laboratory.
- Palantir Technologies and Ginkgo Bioworks are defining opposing models for biosecurity infrastructure.
- Ginkgo Bioworks was part of the medical sector, and its stock outperformed the S&P 500 gain on June 26, 2025.
- Foundry, Ginkgo Bioworks, and CodeBase are proprietary cell programming platforms.
- Ginkgo Bioworks' stock performance on July 11, 2025, lagged the S&P 500 gain but led the Medical sector's gain.
- Ginkgo Bioworks stock outperformed the S&P 500 gain on July 17, 2025, contrasting with a sector loss.
- RAC provides modular hardware and Catalyst scheduling software to clients in the biopharma sector, including Ginkgo Bioworks.
- RAC automation enables high-throughput ADME profiling for Ginkgo Bioworks, which performs all work within the United States.
- Ginkgo Bioworks stock trailed the S&P 500 on July 26, 2025, despite a market uptick, while operating within the broader medical and biomedical industries.
- Ginkgo Bioworks began using Instagram and LinkedIn for its social media and professional networking presence.
- Jason Kelly is co-founder and CEO of Ginkgo Bioworks.
- Ginkgo Bioworks reported operational challenges, including decreased R&D and G&A expenses and difficulties securing international contracts.
- Illumina, Twist Bioscience, Ginkgo Bioworks, Amyris, Cargill, Moderna, and Vertex Pharmaceuticals are all key players in the AI in Synthetic Biology Market.
- Zacks provided stock analysis reports on Ginkgo Bioworks on August 13, 2025.
- Ginkgo Bioworks announced the settlement of shareholder derivative actions on August 30, 2025.
- Ginkgo Bioworks and Apheris formed a strategic partnership to launch the Antibody Developability Consortium.
- Ginkgo Bioworks, Tangible Scientific, and Inductive Bio co-developed the ADME-One platform.